Table 1 Characteristics in patients with metastatic castration-sensitive prostate cancer.

From: Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project

Characteristics

n = 68

Median age, years (IQR)

73 (69–79)

Median PSA level, ng/ml (IQR)

254 (72.4–992)

NA

1

ISUP grade group, n (%)

 ≤ III

5 (7.4%)

 IV

23 (33.8%)

 V

40 (58.8%)

Metastasis, n (%)

 Synchronous

66 (97.1%)

 Metachronous

2 (2.9%)

Prior local treatment, n (%)

 Absence

61 (89.7%)

 Curative radiation

7 (10.3%)

Lymph node metastasis, n (%)

 Absence

23 (33.8%)

 Presence

45 (66.2%)

Bone metastasis, n (%)

 Absence

13 (19.1%)

 1

5 (7.4%)

 2 or 3

10 (14.7%)

 ≥ 4

40 (58.8%)

Lung metastasis, n (%)

 Absence

57 (83.8%)

 Presence

11 (16.2%)

Liver metastasis, n (%)

 Absence

66 (97.1%)

 Presence

2 (2.9%)

Treatment, n (%)

 ADT monotherapy

22 (32.4%)

 CAB

10 (14.7%)

 ADT plus docetaxel

8 (11.8%)

 ADT plus abiraterone

15 (22.1%)

 ADT plus enzalutamide

2 (2.9%)

 ADT plus apalutamide

11 (16.2%)

  1. ADT androgen deprivation therapy, CAB combined androgen blockade, IQR interquartile range, ISUP International Sciety of Urological Pathology, NA not available, PSA prostate-specific antigen
Back to article page